Live
- Risk of Middle East escalation
- 50 families quit YSRCP, join TDP
- Nara Bhuvaneshwari to File Nomination Papers on Behalf of TDP Chief Chandrababu in Kuppam
- Tamil Nadu BJP Chief Announces End Of Dravidian Politics, Foresees BJP Surge
- YS Jagan's Memanta Siddham Bus Yatra begins in Rajapuram, to enter Kakinada by evening
- Not just promises, look for capacity to deliver them
- Sujana Chowdary files papers for Vijayawada West
- Unlocking the Potential of FASTag: Enhancing Parking Solutions with RFID Technology
- TDP-BJP-JSP leaders file Lokesh’s nomination
- Hyderabad: Opposition indulging in divisive politics says BJP MP Laxman
UK to roll out COVID-19 antiviral drug trial this month -Health Security Agency
UK to roll out COVID-19 antiviral drug trial this month
Britain will start to roll out Merck's molnupiravir COVID-19 antiviral pill through a drug trial later this month, Susan Hopkins, Chief Medical Adviser at the UK Health Security Agency said on Sunday. "It is still likely to be a couple of months away."
Britain will start to roll out Merck's molnupiravir COVID-19 antiviral pill through a drug trial later this month, Susan Hopkins, Chief Medical Adviser at the UK Health Security Agency said on Sunday. Last week Britain became the first country in the world to approve the potentially game-changing COVID-19 antiviral pill, jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics.
The government said in October it had secured 480,000 courses of the Merck drug, as well as 250,000 courses of an antiviral pill developed by Pfizer Inc. Asked about the molnupiravir approval, Hopkins told BBC television: "That is great news and it will start to be rolled out through a drug trial in the end of this month/the beginning of December."
Hopkins said all the trials so far had been done with the unvaccinated, so this would help understand how it will work in the wider vaccinated population. "The new Pfizer drug is probably not going to be licensed until the new year some time," she added. "It is still likely to be a couple of months away."
